- Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
- Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Dr. Reddy’s Q4 & Full Year FY24 Financial Results
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
- Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
More ▼
Key statistics
On Friday, Dr Reddy's Laboratories Ltd (DRREDDY:NSI) closed at 5,791.85, -10.98% below its 52-week high of 6,505.90, set on Feb 28, 2024.
52-week range
Open | 5,899.95 |
---|---|
High | 5,904.65 |
Low | 5,752.85 |
Bid | 5,764.30 |
Offer | 5,791.85 |
Previous close | 5,873.75 |
Average volume | 562.87k |
---|---|
Shares outstanding | 166.53m |
Free float | 118.18m |
P/E (TTM) | 17.31 |
Market cap | 964.51bn INR |
EPS (TTM) | 334.61 INR |
Annual div (ADY) | 40.00 INR |
---|---|
Annual div yield (ADY) | 0.69% |
Div ex-date | Jul 11 2023 |
Div pay-date | Aug 26 2023 |
Next div ex-date | Jul 16 2024 |
Next div pay-date | Aug 28 2024 |
Data delayed at least 15 minutes, as of May 31 2024 11:28 BST.
More ▼